Natalia Petushkova

Dr. Natalia Petushkova

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2005 in Toxicology in Vitro
Verified
Journal Article
Closed access
IKI.P. Kanaeva
I.P. Kanaeva
NPNatalia Petushkova
Natalia Petushkova
ALA.V. Lisitsa
A.V. Lisitsa
Petr G. LokhovPetr G. Lokhov
Petr G. Lokhov
VZV.G. Zgoda
V.G. Zgoda
AAA.I. Archakov
A.I. Archakov

11 May 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NPNatalia Petushkova
Natalia Petushkova
VZVictor G Zgoda
Victor G Zgoda
MPMikhail A Pyatnitskiy
Mikhail A Pyatnitskiy
OLOlesya V Larina
Olesya V Larina
NTNadezhda B Teryaeva
Nadezhda B Teryaeva
ALAndrey V Lisitsa
Andrey V Lisitsa
Liquid chromatography-tandem mass spectrometry was used to analyze plasma proteins of volunteers (control) and patients with glioblastoma multiform (GBM). A database search was pre-set with a variable post-translational modification (PTM): phosphorylation, acetylation or ubiquitination. There were no significant differences between the control and the GBM groups regarding the number of protein identifications, sequence coverage or number of PTMs. However, in GBM plasma, we unambiguously observed a decreased fraction in post-translationally modified peptides identified with high quality. The disease-specific PTM patterns were extracted and mapped to the set of FDA-approved plasma protein markers. Decreases of 46% and 24% in the number of acetylated and ubiquitinated peptides, respectively, were observed in the GBM samples. Significance of capturing disease-associated patterns of protein modifications was envisaged.

1 August 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NPNatalia Petushkova
Natalia Petushkova
MPMikhail A Pyatnitskiy
Mikhail A Pyatnitskiy
VRVladislav A. Rudenko
Vladislav A. Rudenko
OLOlesya V. Larina
Olesya V. Larina
OTOxana Trifonova
Oxana Trifonova
ALAndrey V. Lisitsa
Andrey V. Lisitsa
There are two ways that statistical methods can learn from biomedical data. One way is to learn classifiers to identify diseases and to predict outcomes using the training dataset with established diagnosis for each sample. When the training dataset is not available the task can be to mine for presence of meaningful groups (clusters) of samples and to explore underlying data structure (unsupervised learning). We investigated the proteomic profiles of the cytosolic fraction of human liver samples using two-dimensional electrophoresis (2DE). Samples were resected upon surgical treatment of hepatic metastases in colorectal cancer. Unsupervised hierarchical clustering of 2DE gel images (n = 18) revealed a pair of clusters, containing 11 and 7 samples. Previously we used the same specimens to measure biochemical profiles based on cytochrome P450-dependent enzymatic activities and also found that samples were clearly divided into two well-separated groups by cluster analysis. It turned out that groups by enzyme activity almost perfectly match to the groups identified from proteomic data. Of the 271 reproducible spots on our 2DE gels, we selected 15 to distinguish the human liver cytosolic clusters. Using MALDI-TOF peptide mass fingerprinting, we identified 12 proteins for the selected spots, including known cancer-associated species. Our results highlight the importance of hierarchical cluster analysis of proteomic data, and showed concordance between results of biochemical and proteomic approaches. Grouping of the human liver samples and/or patients into differing clusters may provide insights into possible molecular mechanism of drug metabolism and creates a rationale for personalized treatment.

2 May 2015 in Proteome Science
Verified
Journal Article
Open access
PDF file
NPNatalia Petushkova
Natalia Petushkova
GKGalina P Kuznetsova
Galina P Kuznetsova
OLOlesya V Larina
Olesya V Larina
ЮKЮлия Сергеевна Kisrieva
Юлия Сергеевна Kisrieva
NSNatalia F Samenkova
Natalia F Samenkova
ALAndrey V Lisitsa
Andrey V Lisitsa
Vitellogenin (Vtg) is the major egg yolk protein (YP) in most oviparous species and may be useful as an indicator in ecotoxicological testing at the biochemical level. In this study, we obtained detailed information about the Vtgs of Danio rerio embryos by cutting SDS-PAGE gel lanes into thin slices, and analyzing them slice-by-slice with (MALDI-TOF) mass spectrometry. We conducted three proteomic analyses, comparing embryonic Danio rerio Vtg cleavage products after exposure for 48 h to CdSecore/ZnSshell quantum dots (QDs), after exposure to a mixture of the components used for quantum dot synthesis (MCS-QDs), and in untreated embryos. The Vtg mass spectrometric profiles of the QDs-treated embryos differed from those of the unexposed or MCS-QDs-treated embryos. This study demonstrates the possible utility of Vtg profiling in D. rerio embryos as a sensitive diagnostic tool to estimate nanoparticle toxicity.

1 September 2006 in Toxicology in Vitro
Verified
Journal Article
Closed access
NPNatalia Petushkova
Natalia Petushkova
IKI.P. Kanaeva
I.P. Kanaeva
ALA.V. Lisitsa
A.V. Lisitsa
GSG.F. Sheremetyeva
G.F. Sheremetyeva
VZV.G. Zgoda
V.G. Zgoda
AAA.I. Archakov
A.I. Archakov

15 October 2015 in Clinical and Translational Medicine
Verified
Journal Article
Open access
PDF file
OKOlga Kiseleva
Olga Kiseleva
YRYulia A. Romashova
Yulia A. Romashova
NMNatalia Moskaleva
Natalia Moskaleva
NPNatalia Petushkova
Natalia Petushkova
NTNadezhda B. Teryaeva
Nadezhda B. Teryaeva
ALAndrey V. Lisitsa
Andrey V. Lisitsa
Background: The development of commercially available panels for human blood plasma screening via selected reaction monitoring (SRM) offers reliable, cost‐efficient and highly‐standardized discovery and validation of protein biomarkers. However, protein detection by SRM can be hampered by interfering peptide fragment ions. To estimate the influence of interference on protein detection, we performed different types of sample preparation and implemented SRM measurements for well‐characterized protein targets approved by the US Food and Drug Administration.Methods: We used the PlasmaDeepDive™ SRM assay from BiognoSYS AG for absolute quantification of 18 proteins in 19 samples of human plasma using three different protocols for sample preparation. SRM measurements were performed using iRT standards for retention time normalization and isotopically‐labeled reference peptides for absolute quantification. SpectroDive™ software was used for automated detection of reliable peak groups.Results: Fourteen targeted proteins were quantitatively measured in more than half of the samples. Depletion of highly‐abundant plasma proteins and peptide fraction clean‐up on centrifuge plates resulted in detection of all 18 targeted proteins in femtomolar to picomolar concentrations.Conclusions: It was shown that commercially designed SRM kits are suitable for SRM detection of well‐established plasma/serum biomarkers.